Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

• Objective: To review appropriate pharmacologic management for patients with newly diagnosed type 2 diabetes. • Methods: Qualitative assessment of the literature. • Results: Intensive control of blood glucose in patients with type 2 diabetes has been shown to reduce the prevalence and incidence of microvascular disease but may not be sufficient to reduce cardiovascular events. Few oral antidiabetic agents have been evaluated for effect on cardiovascular outcomes; however, metformin and acarbose are both associated with reduced morbidity and, in the case of metformin, mortality related to cardiovascular disease. Aggressive management of lipids and blood pressure have also been shown to reduce cardiovascular morbidity and mortality in patients with type 2 diabetes. • Conclusions: In patients early in the course of type 2 diabetes, choice of pharmacologic agent to control blood glucose can often be guided by determination of cardiovascular risk status. Most patients will require combination therapy to control blood glucose, blood pressure, and lipid levels.


Journal article


Journal of Clinical Outcomes Management

Publication Date





392 - 404